References
- LeeJMLedermannJAKohnECPARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesAnn Oncol2014251324024225019
- LiuJFKonstantinopoulosPAMatulonisUAPARP inhibitors in ovarian cancer: current status and future promiseGynecol Oncol2014133236236924607283
- FongPCBossDSYapTAInhibition of poly (ADP-ribose) polymerase in tumors from BRCA carriersN Engl J Med200936112313419553641
- FDAFDA Briefing Document Oncologic Drugs Advisory Committee Meeting Available from: www.fda.govAccessed August 28, 2015
- MateoJFriedlanderMSessaCAdministration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationEur J Cancer201349S161
- AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
- RolfoCSwaislandHLeunenKEffect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumorsAdv Ther20153251052226048134
- GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
- LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
- KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
- OzaAMCibulaDBenzaquenAOOlaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLancet Oncol2015161879725481791
- LiuJFBarryWTBirrerMCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 studyLancet Oncol201415111207121425218906
- DeanEMiddletonMRPwintTPhase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursBr J Cancer201210646847422223088
- KayeSBLubinskiJAngJEPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA 1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
- Van der NollRMarchettiSSteeghsNLong-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advance breast, ovarian, or fallopian tube cancerBr J Cancer201511339640226180927
- Clinicaltrials.govOlaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) Available from: www.clinicaltrials.govAccessed August 21, 2015
- Clinicaltrials.govOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Available from: www.clinicaltrials.govAccessed August 21, 2015
- MarquesMBeauchampM-CFleuryHChemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitorsBMC Med20151321726354718